Achilles Therapeutics Reports First Patient Dosing of Higher-Dose cNeT in P-I/IIa (CHIRON) Trial for the Treatment of Advanced Non-Small Cell Lung Cancer
Shots:
- The first patient has been dosed in an ongoing P-I/IIa (CHIRON) trial to evaluate the safety, tolerability & clinical activity of cNeT therapy as monothx. in adult patients with advanced metastatic NSCLC. cNeT was manufactured with higher-dose VELOS Process 2
- Following the IDMC recommendation, the company initiates the patient enrollment in cohort B of the P-I/IIa (THETIS) trial to evaluate cNeT therapy as monothx. & in combination with a PD-1 checkpoint inhibitor for the treatment of metastatic MM
- Additionally, the results from the higher-dose cohorts in (CHIRON) and (THETIS) trial for cNeT monothx. and combination results from (THETIS) cohort B are expected in H2’22
Ref: Globenewswire | Image: Achilles
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
